leflunomide has been researched along with Granuloma in 3 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Granuloma: A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Effective treatment of sarcoidosis potentially requires simultaneous modulation both M1/M2 polarization instead of suppressing one pathway over the other to restore immune competent and inactive (M0) macrophages." | 2.58 | Potential immunotherapies for sarcoidosis. ( Crouser, ED; Le, V, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Le, V | 1 |
| Crouser, ED | 1 |
| Baughman, RP | 1 |
| Lower, EE | 1 |
| Cornillier, H | 1 |
| Kervarrec, T | 1 |
| Tabareau-Delalande, F | 1 |
| Mammou, S | 1 |
| Jonville Bera, AP | 1 |
| Machet, L | 1 |
2 reviews available for leflunomide and Granuloma
| Article | Year |
|---|---|
Potential immunotherapies for sarcoidosis.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Granuloma; Humans; Immunotherapy; Leflunom | 2018 |
Treatment of Sarcoidosis.
Topics: Anti-Inflammatory Agents; Azathioprine; Clinical Trials as Topic; Drug Administration Schedule; Gran | 2015 |
1 other study available for leflunomide and Granuloma
| Article | Year |
|---|---|
Interstitial granulomatous dermatitis occurring in a patient with SAPHO syndrome one month after starting leflunomide, and subsequently disappearing with ustekinumab.
Topics: Acquired Hyperostosis Syndrome; Adult; Dermatitis; Dermatologic Agents; Drug Eruptions; Female; Gran | 2016 |